Γ
Content Highlights || Full Agenda
Keynote

8:50 AM

-

9:10 AM

AIxBIO

Engineering Cell Fate: A Foundation Model to Transform Biology into an Engineering Discipline

AlphaFold cracked the code of protein structure. The next major frontier is decoding the dynamic behavior of the living cell itself. A fundamental challenge in modern biology is that of precise, engineered cellular control. Cells possess their own language for communicating with each other -- cell signaling -- which directs core biological processes like development and is frequently dysregulated in disease. Remarkably, biology achieves this complexity using a surprisingly concise vocabulary: only around 20 fundamental molecular signaling pathways have been identified to date. It is the combinations and orders in which they are used that underlies how such a small number of pathways can give rise to the staggering diversity of human cell types and states. In principle, because these pathways are readily manipulated by small molecules, they provide a potent mechanism through which we could control cellular decision-making. However, despite decades of effort, we have not yet deciphered the grammar of this language. Today, the effects of a given signal are largely determined through an empirical, trial-and-error process -- due to two compounding challenges: combinatorial complexity and context dependence. This talk outlines Cellular Intelligence's solution: the construction of the first Universal Virtual Cell-Signaling Model, a platform intended to compute how any cell state will change in response to external signals. By combining the paradigm of developmental biology -- nature's own proving ground -- with our proprietary multiplexing platform, we transform cell signaling from an empirical art into an engineering discipline built for therapeutic design. We aim to unlock high-impact applications: from guided cell therapies that replace lost tissues, to context-specific drug response prediction, to new ways of modeling disease as signaling network failures. Our goal is to understand, predict, and ultimately control cellular behavior.

Keynote

8:50 AM

-

9:10 AM

AIxBIO

Engineering Cell Fate: A Foundation Model to Transform Biology into an Engineering Discipline

AlphaFold cracked the code of protein structure. The next major frontier is decoding the dynamic behavior of the living cell itself. A fundamental challenge in modern biology is that of precise, engineered cellular control. Cells possess their own language for communicating with each other -- cell signaling -- which directs core biological processes like development and is frequently dysregulated in disease. Remarkably, biology achieves this complexity using a surprisingly concise vocabulary: only around 20 fundamental molecular signaling pathways have been identified to date. It is the combinations and orders in which they are used that underlies how such a small number of pathways can give rise to the staggering diversity of human cell types and states. In principle, because these pathways are readily manipulated by small molecules, they provide a potent mechanism through which we could control cellular decision-making. However, despite decades of effort, we have not yet deciphered the grammar of this language. Today, the effects of a given signal are largely determined through an empirical, trial-and-error process -- due to two compounding challenges: combinatorial complexity and context dependence. This talk outlines Cellular Intelligence's solution: the construction of the first Universal Virtual Cell-Signaling Model, a platform intended to compute how any cell state will change in response to external signals. By combining the paradigm of developmental biology -- nature's own proving ground -- with our proprietary multiplexing platform, we transform cell signaling from an empirical art into an engineering discipline built for therapeutic design. We aim to unlock high-impact applications: from guided cell therapies that replace lost tissues, to context-specific drug response prediction, to new ways of modeling disease as signaling network failures. Our goal is to understand, predict, and ultimately control cellular behavior.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: